雷珠单抗联合激光治疗视网膜分支静脉阻塞所致黄斑水肿临床疗效分析

目的 探讨分析雷珠单抗联合激光治疗视网膜分支静脉阻塞所致黄斑水肿的临床疗效。方法 选取2015年7月至2018年1月惠州市第三人民医院眼科收治的84例视网膜分支静脉阻塞所致黄斑水肿患者随机分为观察组和对照组,对照组仅给予激光治疗,观察组给予雷珠单抗联合激光治疗,比较两组患者临床疗效,治疗前、治疗后6个月logMAR BCVA、CMT值,并发症发生情况。结果 观察组患者临床疗效总有效率为95.24%,较对照组显著提高,差异具有统计学意义(P＜0.05),治疗前两组logMAR BCVA、CMT值差异无统计学意义(P＞0.05),治疗后6个月两组患者logMAR BCVA、CMT值均显著下降,且治疗后6个月观察组患者logMAR BCVA、CMT值下降更显著,差异具有统计学意义(P＜0.05),观察组并发症发生显著低于对照组,差异具有统计学意义(P＜0.05)。结论 雷珠单抗联合激光治疗视网膜分支静脉阻塞所致黄斑水肿疗效显著,减小黄斑中心凹厚度,促进患者视力恢复,值得推广。

Clinical analysis of treatment of macular edema caused by retinal branch vein occlusion with ranibizumab combined with laser

Objective To investigate the clinical efficacy of ranibizumab combined with laser in the treatment of macular edema caused by branch retinal vein occlusion.Methods From July 2015 to January 2018,84 patients with macular edema caused by branch retinal vein occlusion were randomly divided into observation group and control group.The control group was given only laser treatment,and the observation group was given ranibizumab combined with laser treatment.Results The total effective rate of clinical observation in the observation group was 95.24%,which was significantly higher than that of the control group,and the difference was statistically significant (P＜0.05).There was no significant difference in logMAR BCVA and CMT between the two groups before treatment (P＞0.05).The logMAR BCVA and CMT values of the two groups were significantly decreased at 6 months after treatment,and the logMAR BCVA and CMT values were significantly lower in the observation group at 6 months after treatment.The difference was statistically significant (P＜0.05).The incidence was significantly lower than that of the control group,and the difference was statistically significant (P＜0.05).Conclusion The effect of ranibizumab combined with laser on macular edema caused by branch retinal vein occlusion is significant,reducing the thickness of foveal fovea and promoting vision recovery.It is worthy of promotion.